Hangzhou Tigermed Consulting Co Ltd
03347
Company Profile
Business description
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's offered services include bioanalytical, medical writing, biostatistical analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.
Contact
Block 8, No. 19 Jugong Road
Room 2001-2010, 20th Floor
Xixing Sub-District, Binjiang District
Hangzhou310053
CHNT: +86 57128887227
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
11,130
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Which of the 3 giant AI IPOs should you buy?
OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,774.90 | 124.80 | -1.40% |
| CAC 40 | 7,981.27 | 164.33 | 2.10% |
| DAX 40 | 23,298.89 | 618.85 | 2.73% |
| Dow JONES (US) | 46,565.74 | 224.23 | 0.48% |
| FTSE 100 | 10,364.79 | 188.34 | 1.85% |
| HKSE | 24,960.25 | 333.78 | -1.32% |
| NASDAQ | 21,840.95 | 250.32 | 1.16% |
| Nikkei 225 | 52,444.58 | 1,295.10 | -2.41% |
| NZX 50 Index | 12,902.15 | 76.28 | 0.59% |
| S&P 500 | 6,575.32 | 46.80 | 0.72% |
| S&P/ASX 200 | 8,579.50 | 105.50 | -1.21% |
| SSE Composite Index | 3,915.01 | 33.54 | -0.85% |